Sandoz US News


New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product

Holzkirchen, December 5, 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced data from the ASSIST-FL trial. The confirmatory safety and efficacy study shows GP2013 met its primary endpoint of overall response rate (ORR), demonstrating equivalence with the reference product, MabThera®*, in 629 patients. Results were presented at the 58th Annual Meeting of the American Society of Hematology (ASH).

Sandoz to donate up to USD 10 million of high-quality generic medicines annually to Americares to increase access to medicines

Princeton, New Jersey, November 22, 2016. Sandoz today announced a collaboration to increase access to medicines by donating up to USD 10 million of stock annually to Americares, a health-focused relief and development organization that responds to people affected by poverty or disaster with life-changing health programs, medicine and medical supplies.

Sandoz launches authorized generic version of Beyaz®

Sandoz today announced the U.S. market introduction of the authorized generic version of Beyaz® (drospirenone/ethinyl estradiol/ levomefolate calcium tablets and levomefolate calcium tablets) mg/0.02 mg/0.451 mg and 0.451 mg, by Bayer

Sandoz Careers


Our people are our greatest resource. We are always looking for new colleagues to share in our passion and commitment to making the world a healthier place.

 Learn more about a career with Sandoz in the US


Vets Hiring 300

Transitioning to civilian service soon? Consider a career with Sandoz, a Novartis company. Learn about our mission, and why you should explore being a part of our team.




Slideshow Background Images